Patients who struggle with chronic painful diabetic neuropathy are invited to join a study at the University of Arkansas for Medical Sciences (UAMS) centering on a spinal cord stimulation device designed to reduce the pain.
Covered by the Pine Bluff Commercial, the study is being led at UAMS by Erika Petersen, M.D., a neurosurgeon and clinical investigator. This study is being conducted across the United States. In Arkansas, where an estimated 363,000 people have type 2 diabetes, about 73,000 of those residents (20 percent) would be expected to have painful diabetic peripheral neuropathy. The number could be higher — a National Institutes of Health-funded study in five rural Arkansas counties concluded that diabetic peripheral neuropathy was alarmingly underdiagnosed. The device, Senza® Spinal Cord Stimulation system, was developed by Nevro. It works by sending electrical pulses to interrupt pain signals and provide pain relief.
Who is Nevro? Founded in 2006, Redwood City, CA-based Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro’s proprietary HF10 therapy. The company went public in 2016. We include financial snapshot from Yahoo Finance. Revenues total $377 million with a $-13.93 million loss. At present stock price market cap $1.42 billion.